Nostrum Biodiscovery

About:

Creating new drugs through AI and molecular modeling

Website: http://www.nostrumbiodiscovery.com

Twitter/X: hellonostrum

Top Investors: Santander, Centre for the Development of Industrial Technology (CDTI)

Description:

Nostrum is a biotech company working together with several major pharmaceutical companies in Europe and the US and has a wide knowledge of the requirements of pharmaceutical companies working in rational drug design. Nostrum advantages are its technologies, allowing the saving of costs and the acceleration of the whole process. Secondly, the level of calculation and prediction capacity by computation, which directly impacts research reliability. Lastly, the team experience and the research excellence which has been strongly demonstrated by the internationally-recognized institutions that support this project for years now.

Total Funding Amount:

712000 EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Barcelona, Catalonia, Spain

Founded Date:

2015-12-04

Contact Email:

hello(AT)nostrumbiodiscovery.com

Founders:

Modesto Orozco, Víctor Guallar Tasies

Number of Employees:

11-50

Last Funding Date:

2017-01-02

IPO Status:

Private

Industries:

© 2025 bioDAO.ai